View from the cutting-edge
Posted: April 3, 2020 | By admin
SHARE ME
CureVac targets mRNA-based coronavirus vaccine
TÜBINGEN, Germany – A new frontier of promise has emerged in the global drive toward a vacine against COVID-19.
CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, has confirmed major progress with its drive toward the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.
Working with nature
“Nature has invented mechanisms to activate our immune system against infectious diseases," explains Mariola Fotin-Mleczek, Chief Technology Officer of CureVac. "With our unique messenger RNA technology we mimic nature and give our body the information how to fight against the virus. The combination of mRNA science, disease understanding, formulation and production expertise make CureVac a unique player to fight against any infectious disease, no matter whether they are seasonal or pandemic.”
Based on its inherent mode of action, CureVac sees mRNA as one of the most potent molecules to provide fast and efficient solutions in outbreak scenarios, such like the Coronavirus. With in-house expertise of over two decades and the company’s deep scientific understanding CureVac is leveraging its vaccine platform to focus on developing a potent, efficacious and safe and fast to produce vaccine against Covid-19.